A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Inclusion Criteria:

Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)
At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening)
Neurologic stability for greater than or equal to (>/=) 30 days prior to both screening and baseline
Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive

Exclusion Criteria:

Primary progressive multiple sclerosis
Disease duration of more than 10 years in patients with EDSS score less than or equal to ( Contraindications for MRI
Known presence of other neurological disorders which may mimic multiple sclerosis
Pregnancy or lactation
Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
History of or currently active primary or secondary immunodeficiency
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
Active infection, or history of or known presence of recurrent or chronic infection (for example, hepatitis B or C, Human Immunodeficiency Virus [HIV], syphilis, tuberculosis)
History of progressive multifocal leukoencephalopathy
Contraindications to or intolerance of oral or IV corticosteroids
Contraindications to Rebif or incompatibility with Rebif use